Immunotherapy setback for AstraZeneca – Seeking Alpha
|
Immunotherapy setback for AstraZeneca
Seeking Alpha AstraZeneca (NYSE:AZN) -15% premarket after the trial of its new lung cancer drug failed to reach its "endpoints" for progression free survival – the length for which people go without their condition worsening. The study, known as Mystic, featured an … |
